Immunogenicity of Bcl-2 in patients with cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• B-cell lymphoma 2 (Bcl-2) is a key regulator of apoptosis, frequently overexpressed in various cancers.
• Bcl-2 targeted therapies, including antisense oligonucleotides and small-molecule inhibitors, show preclinical and clinical promise.
• Cancer immune escape mechanisms can involve Bcl-2 downregulation, highlighting its importance in tumor growth.

Purpose of the Study:

• To investigate spontaneous T-cell reactivity against the Bcl-2 protein in cancer patients.
• To determine if Bcl-2-reactive T cells possess cytotoxic effector functions.
• To evaluate Bcl-2 as a potential target for novel anticancer immunotherapies.

Main Methods:

• Analysis of peripheral blood from patients with diverse cancer types (pancreatic, breast, AML, CLL).
• Characterization of T-cell responses directed against Bcl-2.
• Assessment of the specificity and cytotoxic activity of Bcl-2-reactive T cells.

Main Results:

• Spontaneous T-cell reactivity against Bcl-2 was identified in peripheral blood of patients with unrelated tumor types.
• These Bcl-2-reactive T cells were confirmed to be peptide-specific.
• The identified T cells demonstrated cytotoxic effector functions against Bcl-2 expressing targets.

Conclusions:

• Bcl-2 is a viable and broadly applicable target for anticancer immunotherapy.
• Bcl-2-reactive T cells represent a promising avenue for developing novel immunotherapeutic strategies.
• Combining Bcl-2-targeted immunotherapy with conventional treatments like chemotherapy and radiotherapy may enhance efficacy.